Logo image of MTP

MIDATECH PHARMA PLC-ADR (MTP) Stock Fundamental Analysis

NASDAQ:MTP - Nasdaq - US59564R5000 - ADR - Currency: USD

0.2851  -0.06 (-18.52%)

After market: 0.2801 -0.01 (-1.75%)

Fundamental Rating

1

Taking everything into account, MTP scores 1 out of 10 in our fundamental rating. MTP was compared to 551 industry peers in the Biotechnology industry. MTP may be in some trouble as it scores bad on both profitability and health. MTP is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

MTP had negative earnings in the past year.
MTP had a negative operating cash flow in the past year.
MTP Yearly Net Income VS EBIT VS OCF VS FCFMTP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -5M -10M -15M -20M

1.2 Ratios

The profitability ratios for MTP are negative, so there is not much use analyzing them.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MTP Yearly ROA, ROE, ROICMTP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 -100 -200 -300

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for MTP so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MTP Yearly Profit, Operating, Gross MarginsMTP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -2K -4K -6K

More info and screens

3

2. Health

2.1 Basic Checks

MTP does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MTP has been increased compared to 1 year ago.
MTP has a worse debt/assets ratio than last year.
MTP Yearly Shares OutstandingMTP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M
MTP Yearly Total Debt VS Total AssetsMTP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M

2.2 Solvency

MTP has an Altman-Z score of -12.33. This is a bad value and indicates that MTP is not financially healthy and even has some risk of bankruptcy.
MTP has a Altman-Z score of -12.33. This is amonst the worse of the industry: MTP underperforms 81.14% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that MTP is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.07, MTP is doing worse than 62.44% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z -12.33
ROIC/WACCN/A
WACC6.79%
MTP Yearly LT Debt VS Equity VS FCFMTP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 20M 40M

2.3 Liquidity

MTP has a Current Ratio of 5.28. This indicates that MTP is financially healthy and has no problem in meeting its short term obligations.
MTP's Current ratio of 5.28 is in line compared to the rest of the industry. MTP outperforms 47.70% of its industry peers.
A Quick Ratio of 5.28 indicates that MTP has no problem at all paying its short term obligations.
MTP has a Quick ratio of 5.28. This is comparable to the rest of the industry: MTP outperforms 48.65% of its industry peers.
Industry RankSector Rank
Current Ratio 5.28
Quick Ratio 5.28
MTP Yearly Current Assets VS Current LiabilitesMTP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 5M 10M 15M 20M

More info and screens

1

3. Growth

3.1 Past

MTP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.43%, which is quite impressive.
Looking at the last year, MTP shows a quite strong growth in Revenue. The Revenue has grown by 11.98% in the last year.
The Revenue for MTP have been decreasing by -15.26% on average. This is quite bad
EPS 1Y (TTM)58.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.63%
Revenue 1Y (TTM)11.98%
Revenue growth 3Y-33.19%
Revenue growth 5Y-15.26%
Sales Q2Q%16.71%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MTP Yearly Revenue VS EstimatesMTP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2M 4M 6M 8M
MTP Yearly EPS VS EstimatesMTP Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 -20 -40 -60 -80 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MTP reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MTP Price Earnings VS Forward Price EarningsMTP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MTP Per share dataMTP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MTP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MIDATECH PHARMA PLC-ADR

NASDAQ:MTP (3/24/2023, 8:00:00 PM)

After market: 0.2801 -0.01 (-1.75%)

0.2851

-0.06 (-18.52%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)04-24 2023-04-24
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap1.98M
Analysts45.71
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.48
P/FCF N/A
P/OCF N/A
P/B 0.21
P/tB 0.21
EV/EBITDA N/A
EPS(TTM)-0.96
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)-1.15
OCFYN/A
SpS0.12
BVpS1.34
TBVpS1.34
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 40.39%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.28
Quick Ratio 5.28
Altman-Z -12.33
F-Score2
WACC6.79%
ROIC/WACCN/A
Cap/Depr(3y)40.47%
Cap/Depr(5y)39.25%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.63%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)11.98%
Revenue growth 3Y-33.19%
Revenue growth 5Y-15.26%
Sales Q2Q%16.71%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-5.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y28.58%
OCF growth 3YN/A
OCF growth 5YN/A